Resumo
Differentials
Common
- Minimal change disease
- Focal segmental glomerulosclerosis (FSGS)
- Membranous nephropathy
- Diabetic nephropathy
- Multiple myeloma-associated AL amyloidosis
- IgA nephropathy
Uncommon
- Membranoproliferative (mesangiocapillary) glomerulonephritis
- Amyloidosis
- Lupus nephritis
- Fabry disease
- Alport syndrome
- Nail-patella syndrome
- Malignant hypertension
Contributors
Authors
Panduranga Rao, MD, DNB, MS
Richard D Swartz Collegiate Professor of Nephrology
Professor of Medicine
Department of Medicine
University of Michigan
Ann Arbor
MI
Disclosures
PR declares that he has no competing interests.
Benjamin Wagner, MD
Assistant Professor of Medicine
Department of Medicine
University of Michigan
Ann Arbor
MI
Disclosures
BW declares that he is a co-investigator on "An Open Label Phase 1b Study of Felzartamab in Lupus Nephritis", a study sponsored by HI-Bio.
Acknowledgements
Dr Panduranga Rao and Dr Benjamin Wagner would like to gratefully acknowledge Dr Ruth Pepper, Dr John Connolly, Dr David J.A. Goldsmith, Dr Oliver J. Ziff, and Dr Michael S. Gersch, previous contributors to this topic.
Disclosures
RP, JC, DJAG, OJZ, and MSG declare that they have no competing interests.
Peer reviewers
John Feehally, MBBS, FRCP
Professor of Renal Medicine
The John Walls Renal Unit
Leicester General Hospital
Leicester
UK
Disclosures
JF declares that he has no competing interests.
Judith H. Veis, MD, FASN
Associate Director
Nephrology
Washington Hospital Center
Washington
DC
Disclosures
JHV declares that she has no competing interests.
Catherine Clase, BA, MB, MSC, FRCPC
Associate Professor
Department of Medicine
McMaster University
Ontario
Canada
Disclosures
CC declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Список литературы
Основные статьи
Nishi S, Ubara Y, Utsunomiya Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016 Jun;20(3):342-70.Полный текст Аннотация
Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023 Mar;38(3):877-919.Полный текст Аннотация
Kidney Disease Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4S):1-276.Полный текст
Статьи, указанные как источники
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Использование этого контента попадает под действие нашего заявления об отказе от ответственности